OTCPK:SNDY

Stock Analysis Report

Executive Summary

Solos Endoscopy, Inc., a healthcare instrument company, develops and markets technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment, and management of disease and medical conditions.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Risks

  • Solos Endoscopy has significant price volatility in the past 3 months.
  • Solos Endoscopy's last earnings update was 2679 days ago.
  • Solos Endoscopy is not covered by any analysts.
  • No market cap data available for Solos Endoscopy.

Share Price & News

How has Solos Endoscopy's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

38.6%

OTCPK:SNDY

-1.2%

US Medical Equipment

1.2%

US Market


1 Year Return

20.0%

OTCPK:SNDY

8.7%

US Medical Equipment

1.7%

US Market

SNDY outperformed the Medical Equipment industry which returned 8.7% over the past year.

SNDY outperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

SNDYIndustryMarket
7 Day38.6%-1.2%1.2%
30 Day25.0%1.4%4.9%
90 Day76.5%4.8%3.7%
1 Year20.0%20.0%9.6%8.7%3.9%1.7%
3 Year-27.7%-27.7%70.8%65.5%47.2%37.7%
5 Year-99.6%-99.6%130.4%104.1%60.0%42.4%

Price Volatility Vs. Market

How volatile is Solos Endoscopy's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Solos Endoscopy undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Solos Endoscopy is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Solos Endoscopy has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Examine Solos Endoscopy's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Solos Endoscopy regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Solos Endoscopy expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Solos Endoscopy has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Solos Endoscopy performed over the past 5 years?

0.2%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Solos Endoscopy has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is Solos Endoscopy's financial position?


In this section we usually analyse Solos Endoscopy's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Solos Endoscopy has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of SNDY’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Solos Endoscopy's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is Solos Endoscopy's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Solos Endoscopy's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Solos Endoscopy's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Solos Endoscopy has not reported any payouts.

Unable to verify if Solos Endoscopy's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Solos Endoscopy has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Solos Endoscopy's salary, the management and board of directors tenure and is there insider trading?


CEO

Dom Gatto (57yo)

2.3yrs

Tenure

0

Mr. Dom L. Gatto serves as President, Secretary & Treasurer at Solos Endoscopy, Inc. Mr. Gatto has been Chairman of the Board and Chief Executive Officer at Solos Endoscopy, Inc. since June 2017. Mr. Gatto ...


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Fred Schiemann (67yo)

    CFO & Director

    • Tenure: 0yrs
  • J. Segersten

    Secretary

    • Tenure: 0yrs
  • Dom Gatto (57yo)

    President

    • Tenure: 2.3yrs
  • Gerald Schwebel

    Operations Manager

    • Tenure: 0yrs

Board Members

  • Fred Schiemann (67yo)

    CFO & Director

    • Tenure: 0yrs
  • Dom Gatto (57yo)

    President

    • Tenure: 2.3yrs

Company Information

Solos Endoscopy, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Solos Endoscopy, Inc.
  • Ticker: SNDY
  • Exchange: OTCPK
  • Founded: 1986
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$0
  • Shares outstanding: 0
  • Website: https://www.solosendoscopy.com

Location

  • Solos Endoscopy, Inc.
  • Boston/Dedham Commerce Park
  • 65 Sprague Street
  • Boston
  • Massachusetts
  • 2136
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SNDYOTCPK (Pink Sheets LLC)Common StockUSUSDMar 1998

Biography

Solos Endoscopy, Inc., a healthcare instrument company, develops and markets technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment, and management of  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/15 00:10
End of Day Share Price2019/09/11 00:00
Earnings2012/03/31
Annual Earnings2011/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.